Metrics as of 10/13/2026, 06:40 PM (Berlin time), refresh in progress.
Metagenomi Stock
Metagenomi, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jian Irish
- Employees
- 113
- Market cap
- $36 M
- IPO
- 09/02/2024
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises…
Metagenomi stock: price history
1D
-8.6%
1W
-9.5%
1M
-19.6%
6M
-34.8%
YTD
-42.4%
1Y
-67.3%
2Y
-52.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~8% weaker price swings than usual
Ask the agents about Metagenomi
Analyst assessment of Metagenomi
PRICE TARGET LOW
US$7.00
CONSENSUS
US$14.50
MEDIAN
US$14.50
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/08/2026
Metagenomi stock metrics
P/E
-0.38
P/B
0.32
EV/EBITDA
-0.39
RETURN ON EQUITY
-24.4%
NET MARGIN
10,693.4%
DEBT/EQUITY
0.34
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
67.6%
FLOAT SHARES
25,437,982
AVG. DAILY VOLUME (30D)
163,895
Insider transactions (SEC)
Reid Laurence
Reid Laurence
Irish Jian
Wapnick Pamela
Wein Matthew
Institutional holders
Comparable stocks
Frequently asked questions about Metagenomi stock
What does Metagenomi do?
Metagenomi, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jian Irish, the company employs around 113 people.
The IPO was on 09/02/2024; the stock trades on NASDAQ under the ticker MGX.
What do analysts say about Metagenomi stock?
5 analysts rate the stock, the consensus is Buy (as of 11/08/2026).
The average price target is US$14.50, ranging from US$7.00 to US$22.00, with a median of US$14.50.
This is an external assessment, not a statement by Market Jury.
When does Metagenomi report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does Metagenomi pay a dividend?
No, Metagenomi currently does not pay a dividend.
Which stocks are comparable to Metagenomi?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Metagenomi stock analyzed?
Clicking "Analyze stock" lets five strategies assess Metagenomi against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.